- Conditions
- Graft-versus-host-disease, GVHD, GVHD, Acute
- Interventions
- BMS-986004, Sirolimus, Tacrolimus
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 3
- States / cities
- Duarte, California • Tampa, Florida • Columbus, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1585–1608
of 10,869
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Kaposi's Sarcoma
- Interventions
- VEGF inhibitor PTC299, gene expression analysis, polymerase chain reaction, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy
- Drug · Genetic · Other + 1 more
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 8
- States / cities
- La Jolla, California • Los Angeles, California • Honolulu, Hawaii + 4 more
- Conditions
- Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
- Interventions
- Laboratory Biomarker Analysis, Onalespib, Paclitaxel, Pharmacological Study
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 4
- States / cities
- Lexington, Kentucky • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more
- Conditions
- Advanced Non-small Cell Lung Cancer, HER2 Mutation
- Interventions
- Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 444 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 25
- States / cities
- Newport Beach, California • San Diego, California • San Francisco, California + 20 more
- Conditions
- Heart Failure
- Interventions
- Sentus QP left ventricular lead
- Device
- Lead sponsor
- Biotronik SE & Co. KG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 75
- States / cities
- Fairhope, Alabama • Anchorage, Alaska • Chula Vista, California + 64 more
- Conditions
- Sarcoma
- Interventions
- dactinomycin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, irinotecan hydrochloride, vincristine sulfate, conventional surgery, radiation therapy, filgrastim
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 49 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2019
- U.S. locations
- 143
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 118 more
- Conditions
- Eosinophilic Gastritis, Eosinophilic Duodenitis
- Interventions
- AK002, Placebo
- Drug · Other
- Lead sponsor
- Allakos Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 76
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 70 more
- Conditions
- Primary Generalized Epilepsy
- Interventions
- Cenobamate, Placebo
- Drug
- Lead sponsor
- SK Life Science, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 43
- States / cities
- Phoenix, Arizona • Tuscon, Arizona • Fresno, California + 37 more
- Conditions
- Asthma
- Interventions
- lebrikizumab, placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 62
- States / cities
- Oxford, Alabama • Long Beach, California • Los Angeles, California + 57 more
- Conditions
- NSCLC
- Interventions
- Doxorubicin HCl Inhalation Solution, Docetaxel, Cisplatin
- Drug
- Lead sponsor
- Zivena
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 6
- States / cities
- New Haven, Connecticut • Las Vegas, Nevada • The Bronx, New York + 2 more
- Conditions
- Lung Cancer
- Interventions
- gemcitabine hydrochloride, irinotecan hydrochloride
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2008
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 31 more
- Conditions
- Heart Failure, Hyperkalemia
- Interventions
- Not listed
- Lead sponsor
- Vifor (International) Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,636 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 52
- States / cities
- Little Rock, Arkansas • La Jolla, California • Northridge, California + 46 more
- Conditions
- Hypercholesterolemia
- Interventions
- Placebo (for alirocumab), Alirocumab, Lipid-Modifying Therapy (LMT)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 76
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more
- Conditions
- Myopia
- Interventions
- Atropine 0.1% Ophthalmic Solution, Atropine 0.01% Ophthalmic Solution, Placebo Ophthalmic Solution
- Drug
- Lead sponsor
- Eyenovia Inc.
- Industry
- Eligibility
- 3 Years to 12 Years
- Enrollment
- 438 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Azusa, California + 15 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Tesaglitazar, Pioglitazone
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 110
- States / cities
- Birmingham, Alabama • Columbiana, Alabama • Mobile, Alabama + 107 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Avandamet 6 mg/1500 mg (ttd), Avandamet 4 mg/1000 mg (ttd), Avandamet 2 mg/500 mg (ttd), Avandamet 8 mg/ 2000 mg (ttd), Metformin 500 mg (ttd), Metformin 1000 mg (ttd), Metformin 1500 mg (ttd), Metformin 2000 mg (ttd)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 688 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 71
- States / cities
- Tuscaloosa, Alabama • Gilbert, Arizona • Glendale, Arizona + 65 more
- Conditions
- Osteoarthritis of the Knee
- Interventions
- X0002, Placebo
- Drug
- Lead sponsor
- Lina Xu
- Industry
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 20
- States / cities
- Tempe, Arizona • Carmichael, California • Spring Valley, California + 17 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- GSK4527363, Placebo matching GSK4527363, Belimumab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 143 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- Las Vegas, Nevada • Columbus, Ohio
- Conditions
- Thrombosis, Heparin-induced Thrombocytopenia
- Interventions
- Fondaparinux
- Drug
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Orange, California • Columbus, Ohio + 1 more
- Conditions
- Congenital Heart Diseases, Cardiac Diseases
- Interventions
- Not listed
- Lead sponsor
- Matthias Stuber
- Other
- Eligibility
- Not listed
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 6 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- 125/25 mcg once-daily GSK573719/GW642444, 125mcg once-daily GSK573719, Placebo once-daily
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years to 120 Years
- Enrollment
- 563 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 15
- States / cities
- Mobile, Alabama • Sunset, Louisiana • Plymouth, Minnesota + 12 more
- Conditions
- Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Recurrent Distal Bile Duct Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Liver Carcinoma
- Interventions
- Atezolizumab, Biopsy, Biospecimen Collection, Cobimetinib, Computed Tomography, Magnetic Resonance Imaging, Varlilumab
- Biological · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Duarte, California • Los Angeles, California + 22 more
- Conditions
- Cardiac Transplant Failure, Cardiac Transplant Rejection, Heart Diseases
- Interventions
- Not listed
- Lead sponsor
- CareDx
- Industry
- Eligibility
- 15 Years and older
- Enrollment
- 2,444 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2020
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 27 more
- Conditions
- Neurocognitive, Neuroprotective, Neonatal, Neurodevelopmental Impairment
- Interventions
- Darbepoetin, Placebo
- Drug
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- 1 Hour to 24 Hours
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 12 more